Abstract: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.

Abstract: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.

Abstract: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.

Abstract: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.

Abstract: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.

Abstract: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.

Abstract: Polycondensates which contain tartaric acid derivatives, processes for their preparation and use thereof.The invention relates to polycondensates which consist of at least 95 mol % of recurring structural units of the formula I ##STR1## where R.sup.1 is a 2,3-O-alkylidenetartaric acid derivative (II) or furo[2,5] (V), alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, X is --O-- --NH-- or --S-- and R.sup.2 is 2,3-O-alkylidene-L-threitol (III) or a compound of the formula VI, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, with the proviso that more than 5 mol % of the radicals R.sup.1 and/or R.sup.2 are present in the polycondensate of the formula I, where R.sup.1 is compound of the formula II or R.sup.2 is a compound of the formula III or R.sup.1 is a compound of the formula II and R.sup.2 is a compound of the formula III, or in which more than 5 mol % of the radicals R.sup.1 and R.sup.2 are present in the polycondensate of the formula I, wherea) R.sup.

Abstract: The invention relates to polycondensates which consist of at least 95 mol % of recurring structural units of the formula I ##STR1## where R.sup.1 is a 2,3-O-alkylidenetartaric acid derivative (II) or furo[2,5] (V), alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, X is --O--, --NH-- or --S-- and R.sup.2 is 2,3-O-alkylidene-L-threitol (III) or a compound of the formula VI, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, with the proviso that more than 5 mol % of the radicals R.sup.1 and/or R.sup.2 are present in the polycondensate of the formula I, where R.sup.1 is compound of the formula II or R.sup.2 is a compound of the formula III or R.sup.1 is a compound of the formula II and R.sup.2 is a compound of the formula III, or in which more than 5 mol % of the radicals R.sup.1 and R.sup.2 are present in the polycondensate of the formula I, wherea) R.sup.1 is a compound of the formula V and R.sup.2 is a compound of the formula VI, orb) R.sup.

Abstract: Polycondensates which contain tartaric acid derivatives, processes for their preparation and use thereof.The invention relates to polycondensates which consist of at least 95 mol % of recurring structural units of the formula I ##STR1## where R.sup.1 is a 2,3-O-alkylidenetartaric acid derivative (II) or furo[2,5] (V), alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, X is --O--, --NH-- or --S-- and R.sup.2 is 2,3-O-alkylidene-L-threitol (III) or a compound of the formula VI, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or a heterocycle, with the proviso that more than 5 mol % of the radicals R.sup.1 and/or R.sup.2 are present in the polycondensate of the formula I, where R.sup.1 is compound of the formula II or R.sup.2 is a compound of the formula III or R.sup.1 is a compound of the formula II and R.sup.2 is a compound of the formula III, or in which more than 5 mol % of the radicals R.sup.1 and R.sup.2 are present in the polycondensate of the formula I, wherea) R.sup.